BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 11188938)

  • 1. [Detection of minimal residual disease in acute leukemias by flow cytometry].
    Scolnik MP
    Medicina (B Aires); 2000; 60 Suppl 2():83-6. PubMed ID: 11188938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunophenotyping in acute leukemia: detection of minimal residual disease].
    Pálóczi K; Nahajevszky S; Jakab K; Regéczy N; Gopcsa L; László E; Földi J
    Orv Hetil; 2000 Nov; 141(46):2487-92. PubMed ID: 11126681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukemia-associated phenotypes: their characteristics and incidence in acute leukemia.
    Babusíková O; Glasová M; Koníková E; Kusenda J
    Neoplasma; 1996; 43(6):367-72. PubMed ID: 8996560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flow cytometric determination of leukemia-associated marker combinations for the study of minimal residual disease.
    Babusíková O; Glasová M; Kusenda J; Koníková E; Mésárosová A
    Neoplasma; 1994; 41(6):305-13. PubMed ID: 7870213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiparametric analysis of normal and postchemotherapy bone marrow: Implication for the detection of leukemia-associated immunophenotypes.
    Olaru D; Campos L; Flandrin P; Nadal N; Duval A; Chautard S; Guyotat D
    Cytometry B Clin Cytom; 2008 Jan; 74(1):17-24. PubMed ID: 18061947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Minimal residual disease in childhood acute leukemias].
    Pawińska K; Balwierz W; Baran J
    Przegl Lek; 2006; 63(1):41-3. PubMed ID: 16892899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunophenotyping of acute leukemias: diagnostic and pronostic utility in Abidjan, Côte d'Ivoire].
    Inwoley KA; Sawadogo D; Mizero L; Salou M; Karim N; Sangaré A
    Bull Soc Pathol Exot; 2004; 97(5):319-22. PubMed ID: 15787262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of immunophenotyping on management of acute leukemias.
    Béné MC; Bernier M; Castoldi G; Faure GC; Knapp W; Ludwig WD; Matutes E; Orfao A; van't Veer M
    Haematologica; 1999 Nov; 84(11):1024-34. PubMed ID: 10553164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of FCM-DNA measurement in detecting minimal residual disease in leukemia.
    Zhang RX; Yao EG
    Chin Med J (Engl); 1990 Oct; 103(10):826-30. PubMed ID: 2125256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiparametric flow cytometry in detection of minimal residual disease in acute lymphoblastic leukemia of early B-cell phenotype.
    Mlcáková A; Babusíková O
    Neoplasma; 2003; 50(6):416-21. PubMed ID: 14689062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow.
    Kern W; Danhauser-Riedl S; Ratei R; Schnittger S; Schoch C; Kolb HJ; Ludwig WD; Hiddemann W; Haferlach T
    Haematologica; 2003 Jun; 88(6):646-53. PubMed ID: 12801840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia.
    Campana D; Coustan-Smith E
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):1-19. PubMed ID: 11987913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modern diagnostics in acute leukemias.
    Haferlach T; Kern W; Schnittger S; Schoch C
    Crit Rev Oncol Hematol; 2005 Nov; 56(2):223-34. PubMed ID: 16213152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCR detection of clonal IgH and TCR gene rearrangements at the end of induction as a non-remission criterion in children with ALL: comparison with standard morphologic analysis and risk group classification.
    Scrideli CA; Queiroz RG; Bernardes JE; Valera ET; Tone LG
    Med Pediatr Oncol; 2003 Jul; 41(1):10-6. PubMed ID: 12764736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical significance and prognostic detection of minimal residual disease in acute leukemias].
    Deptała A; Widzyńska I; Kuratowska Z
    Acta Haematol Pol; 1995; 26(4):413-20. PubMed ID: 8571743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia].
    Liu YR; Wang YZ; Chen SS; Chang Y; Fu JY; Li LD; Wang H; Yu H; Jiang B; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):731-6. PubMed ID: 18457262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of minimal residual disease in acute leukemia.
    van der Velden VH; Boeckx N; van Wering ER; van Dongen JJ
    J Biol Regul Homeost Agents; 2004; 18(2):146-54. PubMed ID: 15471219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
    Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
    Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings.
    Voskova D; Schoch C; Schnittger S; Hiddemann W; Haferlach T; Kern W
    Cytometry B Clin Cytom; 2004 Nov; 62(1):25-38. PubMed ID: 15468339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Importance of the detection of minimal residual disease in the management of acute leukemia].
    Mód A; Tamáska J; Adám E; Gidáll J; Poros A; Király A; Natonek K; Pálóczi K; Hollán Z
    Orv Hetil; 1991 Jun; 132(24):1291-6, 1299. PubMed ID: 1857605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.